GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy
"We have demonstrated a very attractive preclinical profile for
GMI-1271, with research
findings presented through four oral presentations and a poster at
the 56th ASH Annual Meeting in
This Phase 1/2, open-label multicenter study is designed to determine
safety, PK and efficacy of GMI-1271 in combination with chemotherapy in
male and female adult patients with AML. Study sites are located in
About AML
Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. AML is the most common type of acute leukemia in adults, and it is estimated that there will be over 18,000 new cases and over 10,000 deaths from the disease in 2014. Unlike other cancers that start in an organ and spread to the bone marrow, AML is known for rapid growth of abnormal white blood cells that gather in the bone marrow and as a result, impede normal blood cell production. While leukemic cells move into the blood, the lack of normal blood cells can cause some of the symptoms of AML, including anemia (shortage of red blood cells resulting in tiredness and weakness), neutropenia (shortage of white blood cells that may lead to increased infections), and thrombocytopenia (shortage of platelets in the blood that may lead to excessive bleeding). Current treatment options for AML are chemotherapy and stem cell transplantation, both of which can destroy cancer cells but do not reduce the related side effects.
About
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Pfizer is the company's development partner for rivipansel, a GlycoMimetics-discovered investigational therapy for pain crisis associated with sickle cell disease, and is preparing to conduct a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271. Actual results may differ materially
from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as
other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20150519006264/en/
Investor Contact:
Phone:
650-888-0902
Email: sannes@annesassociates.com
or
Media
Contact:
Phone: 410-299-3310
Email:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media